BlackRock reports 10.5% Apellis stake on 13G

BlackRock, Inc. has filed a Schedule 13G reporting beneficial ownership of 13,228,073 shares of Apellis Pharmaceuticals Inc. common stock, representing 10.5% of the class.

Rhea-AI Filing Summary

BlackRock, Inc. has filed a Schedule 13G reporting beneficial ownership of 13,228,073 shares of Apellis Pharmaceuticals Inc. common stock, representing 10.5% of the class. BlackRock reports sole power to vote 13,026,072 shares and sole power to dispose of 13,228,073 shares.

The filing states the securities are held by certain BlackRock business units in the ordinary course of business and not for the purpose of changing or influencing control of Apellis. Various underlying clients have rights to dividends or sale proceeds, but no single client exceeds five percent of the outstanding common shares.

Insights

Equity ownership and governance analyst

BlackRock discloses a 10.5% passive stake in Apellis.

BlackRock, Inc. reports beneficial ownership of 13,228,073 Apellis common shares, or 10.5% of the class, with sole voting power over 13,026,072 shares. The position is held across designated business units and reflects aggregated client assets managed by BlackRock.

The certification states the holdings are in the ordinary course of business and are not intended to change or influence control of Apellis Pharmaceuticals Inc., aligning with a passive institutional ownership profile. Economic benefits, such as dividends or sale proceeds, ultimately flow to various underlying clients, none individually above five percent of the common shares.

The disclosure clarifies a significant institutional presence in Apellis’s shareholder base as of 01/31/2026. Future ownership reports from large holders like BlackRock can indicate changes in institutional sentiment or asset allocation when compared across subsequent beneficial ownership filings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Apellis (APLS) shares does BlackRock report owning?

BlackRock reports beneficial ownership of 13,228,073 Apellis common shares. This amount aggregates positions held by certain BlackRock business units and their subsidiaries, representing client assets managed by BlackRock rather than a proprietary trading position by BlackRock itself.

What percentage of Apellis (APLS) does BlackRock’s 13G filing represent?

BlackRock’s Schedule 13G reports ownership of 10.5% of Apellis’ common stock. This percentage reflects 13,228,073 shares beneficially owned as of January 31, 2026, giving BlackRock a significant institutional stake in the company’s outstanding common equity.

What voting and dispositive power does BlackRock have over Apellis (APLS) shares?

BlackRock reports sole voting power over 13,026,072 Apellis shares and sole dispositive power over 13,228,073 shares. It reports no shared voting or shared dispositive power, indicating centralized control of voting and sale decisions within the relevant BlackRock entities.

Is BlackRock’s Apellis (APLS) stake intended to influence control of the company?

The filing states the Apellis shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. BlackRock also notes the holdings are not connected with any transaction aimed at affecting Apellis’ control.

Who ultimately benefits from BlackRock’s Apellis (APLS) shareholdings?

The filing explains that various persons have rights to dividends or sale proceeds from Apellis shares held by BlackRock-managed entities. No single such person has an interest exceeding five percent of the total outstanding common shares, reflecting diversified underlying client ownership.

Why did BlackRock file a Schedule 13G for Apellis (APLS)?

BlackRock filed Schedule 13G because its beneficial ownership of Apellis common stock exceeded the 5% reporting threshold. The passive, ordinary-course certification and institutional profile are consistent with using Schedule 13G instead of the more activist-focused Schedule 13D.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 12:08 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Apellis Pharmaceuticals Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03753U106

(CUSIP Number)

01/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 03753U106

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 13,026,072.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 13,228,073.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,228,073.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.5 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Apellis Pharmaceuticals Inc
(b)	Address of issuer's principal executive offices: 100 FIFTH AVENUE WALTHAM MA 02451
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 03753U106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 13228073
(b)	Percent of class: 10.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 13026072
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 13228073
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Apellis Pharmaceuticals Inc. No one person's interest in the common stock of Apellis Pharmaceuticals Inc is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	02/06/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7